Education
About Us
Working with TipRanks
Follow Us
Omnicell (OMCL)
NASDAQ:OMCL
OMCL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.66 - $55.75
Previous CloseN/A
Volume97.52K
Average Volume (3M)748.43K
Market Cap
$1.39B
Enterprise Value$1.22B
Total Cash (Recent Filing)$381.68M
Total Debt (Recent Filing)$382.55M
Price to Earnings (P/E)64.6
Beta0.29
Next Earnings
Aug 05, 2025EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding46,843,605
10 Day Avg. Volume661,077
30 Day Avg. Volume748,432
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio8.66
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue0.28
Enterprise Value/Gross Profit2.58
Enterprise Value/Ebitda5.59
Forecast
1Y Price Target
$40.40Price Target Upside35.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Omnicell News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceOmnicell has lifted the low end of its Adj EBITDA range for FY25 by $20M, indicating a stronger financial performance outlook.
Product DemandOMCL has executed well over the past few quarters utilizing product innovation and an improved demand environment to drive positive product revenue growth.
Share RepurchaseThe company announced a $75M stock repurchase program, suggesting confidence in the company's stock value.
Bears Say
CFO TransitionVisibility remains challenged with a pending CFO change and still early days in new product growth.
Seasonal Bookings RiskBookings remain an area of risk due to seasonality in the second half.
Tariff RisksThere is a risk that tariffs could revert back to a high rate, which might negatively impact future adjusted EBITDA estimates.
Ownership Overview
2.58% Insiders
32.21% Mutual Funds
15.94% Other Institutional Investors
15.88% Public Companies and Individual Investors
OMCL FAQ
What was Omnicell’s price range in the past 12 months?
Omnicell lowest stock price was $22.66 and its highest was $55.74 in the past 12 months.
What is Omnicell’s market cap?
Omnicell’s market cap is $1.39B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Aug 05, 2025 which is in 66 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on May 06, 2025. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.205 by $0.055.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.27.
How many shares outstanding does Omnicell have?
Omnicell has 46,843,605 shares outstanding.
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of $0.26 in its last earnings report, beating expectations of $0.205. Following the earnings report the stock price went down -15.841%.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in OMCL
Omnicell Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.40 (35.43% Upside)
$40.40 (35.43% Upside)
Blogger Sentiment
Bullish
OMCL Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 157.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $567.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.35%
12-Months-Change
Fundamentals
Return on Equity
1.73%
Trailing 12-Months
Asset Growth
-5.79%
Trailing 12-Months
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
OMCL Company Deck
OMCL Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a mixed picture with strong revenue growth and recurring revenue achievements offset by significant challenges due to tariffs and decreased profitability metrics. The company's strategic pivots towards recurring revenue and customer wins are positive, though the tariff impact is a considerable headwind.Read More>OMCL Stock 12 Month Forecast
Average Price Target
$40.40
▲(35.43%Upside)